Evaluating MMV1593537 as a Novel Antifungal Strategy Against Drug-Resistant Candidozyma (Candida) auris

Project lead

Lysangela Ronalte Alves – Instituto Carlos Chagas (ICC), Fiocruz, Brazil

Co-applicants

Attila Gacser – University of Szeged, Hungary

Geographical focus

Global

Research theme

Microbial Pathogenesis, One Health

Organism/pathogen

Candidozyma (Candida) auris

Lay summary:

The rise of multidrug-resistant fungal pathogens like Candidozyma (Candida) auris poses a serious global health threat, especially for immunocompromised patients. This project aims to explore MMV1593537 as a novel treatment option, either alone or in combination with existing antifungals. MMV1593537 has shown fungicidal activity against Cdz. auris, affecting cell wall integrity and inducing aggregation, with low toxicity in murine macrophages. We will evaluate its efficacy across a diverse set of Cdz. auris isolates and perform proteomic and transcriptomic analyses to uncover its mechanism of action. Synergy with azoles, amphotericin B, and echinocandins will be tested in vitro, with the most promising combinations advanced to Galleria mellonella and murine infection models. Outcomes will include survival and fungal burden in vital organs. These studies aim to establish MMV1593537 as a viable new strategy for treating resistant fungal infections.